Grünenthal's revenue and earnings growth goes steadily on
German pain specialist Grünenthal is continuing its upwards trajectory, with its 2022 full-year results showing record revenue and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA).
The company exceeded its financial and non-financial targets, progressing on its growth path. Net revenues reached 1.7 billion euros ($1.8 billion), an increase of 13% compared to 2021. Adjusted EBITDA was 438 million euros, a rise of 18% over 2021 to a figure that has more than tripled since 2017.
"We continue to invest in researching innovative, non-opioid pain medicines"Grünenthal has also more than tripled its operating cash flow since 2017, positioning the company well to further invest in advancing its R&D pipeline, continuing its M&A strategy and growing the business in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze